Envoy Medical Q2 FY26 net loss attributable to common stockholders widens to $7.27 million; revenue falls 34.62% to $51,000
Reuters2026/08/10 12:07- Envoy Medical posted Q2 net revenue of USD 51,000, down 34.62% from USD 78,000 a year earlier.
- Net loss attributable to common stockholders widened to USD 7.27 million, or USD 0.07 per share, from USD 6.94 million, or USD 0.32.
- R&D expense climbed 26.04% to USD 3.13 million, driven by clinical-trial follow-up activity, PMA module submission fees, and personnel costs.
- Cash totaled about USD 19.68 million at June 30, 2026, up from USD 3.74 million at Dec. 31, 2025.
- Submitted the first of four modular PMA modules to the FDA for the Acclaim cochlear implant; final module with clinical data targeted for Q2 2027.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Pi Network’s PI Defends a Critical Support, Bitcoin (BTC) Reclaims $78K: Weekend Watch
Pons: $20.93 million has been paid to token creators over the past 47 days
XRP’s Crazy August Is Almost Over – September Could Be Even Bigger
Crude oil is "coming back", but refined oil is "not coming back"; the global refining gap is widening.
According to Goldman Sachs, global refined oil exports have declined by about 6 million barrels per day year-on-year, with the Gulf region and Russia contributing three-quarters of the decrease. Unlike crude oil, which can be rerouted, damaged refineries cannot be relocated, and the Gulf region's refined oil exports have only recovered to 40% of pre-war levels. Goldman Sachs expects global refinery utilization rates to recover only by the second half of 2027; based on this, it has more than doubled its forecast for diesel profit margins in 2027.
Crypto prices
More
